MA-BATTERY-VENTURES
17.4.2024 12:01:33 CEST | Business Wire | Press release
Battery Ventures, a global, technology-focused investment firm, announced the acquisition of Labguru (BioData Inc.), the life-science laboratory-data platform, from Holtzbrinck Digital. Terms were not disclosed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240417562351/en/
Labguru provides a comprehensive laboratory data-management hub for planning and tracking; documenting experiments; streamlining lab logistics; and sharing results across teams and organizations. Labguru’s easy-to-use, cloud-based, research-to-production life-science platform combines an Electronic Lab Notebook (ELN), a Laboratory Information Management System (LIMS) and a set of informatics tools to enable and enhance research and production. Labguru is trusted by hundreds of thousands of scientists across the biotechnology, pharmaceutical and advanced-industry segments, as well as researchers at global academic and research institutions.
Labguru will join Battery’s Titian Software to create a global organization that offers an end-to-end solution across life sciences and laboratory applications from research to production, spanning the entire workflow from ELN to inventory and sample management, research, testing and QC workflows.
“Together Titian and Labguru will use the investment by Battery to further support organic growth as well as shape the direction of the group’s future acquisitions, in fulfilling the group vision to become the one-stop shop of the global life-science software market,” said Battery General Partner Jesse Feldman.
“We are excited to bring together Titian and Labguru and to work with the companies’ leaders to provide an integrated laboratory and sample-management offering to researchers,” Feldman said. “The two companies already serve researchers across multiple disciplines at the forefront of science, and we look forward to expanding how we serve our customers.”
Labguru’s executive team, including CEO Ariel Yarnitsky and founder and CTO Jonathan Gross, will remain in their current roles, working alongside the Titian executive team following the transaction.
“We’re excited to join forces with Battery, a long-standing investor with domain expertise across life-science informatics and laboratory automation and leverage their vast experience during Labguru’s next growth phase,” said Yarnitsky. “Specifically, Labguru’s mission to build a leading solution catering to the broad needs of scientists in one coherent and easy-to-use platform becomes even more exciting by joining hands with Titian and with the strong support of Battery. Between the additional capital from Battery and the product and cultural fit with Titian, we could not think of a more suitable partner to propel Labguru forward.”
Founder Gross added: “Partnering with Battery and Titian will accelerate our ability to leverage technology, experience and insights to effectively widen the scope of our platform, benefiting science and scientists. This is an important and dramatic step in Labguru’s journey. Further, with Battery Ventures’ long-standing experience investing in data and AI companies, we have found a valuable partner to help shape our vision as we continue building on Labguru’s suite of artificial intelligence tools.”
Titian Software Founder and Chief Product Officer Edmund Wilson added, “We are delighted to partner with Labguru. Our companies share a common commitment to providing state-of-the-art solutions to the life sciences community, delivered by staff who offer tremendous domain expertise.”
Holtzbrinck Digital played a crucial role in Labguru's development and success. Their vision and support have been instrumental in the company's fast growth and positioning as a tier-1 lab-management software company. "We are extremely happy with Labguru's development over the last years and are proud of the strides we've made together. Finding a partner like Battery, who shares our commitment to innovation and excellence, marks a thrilling next chapter for Labguru," said Marc-Orell Dedorath, head of group M&A at Holtzbrinck.
“We are thrilled to unite two major forces in a market that's only beginning to realize its vast potential,” added Justin Rosner, a principal at Battery. “We look forward to working with the Labguru and Titian teams as we embark on this journey together."
About Labguru (BioData Inc.)
Labguru (BioData Inc.) was founded in 2007 and is the developer of a secure, cloud-based laboratory data management platform for life science research and industry. Labguru is an all-in-one platform that streamlines laboratory operations by recording and managing data and inventory, offering molecular biology and chemistry tools, enabling lab automation, and providing data-driven, AI-assisted insights for increased efficiency. As a trusted tool for more than 120,000 scientists worldwide, we empower the digitalization efforts of customers ranging from start-ups to global life science organizations. To learn more about Labguru, visit www.labguru.com.
About Titian Software
Titian Software was founded in 1999 and is a leading provider of sample management software solutions, catering to the unique needs of research laboratories, biobanks, and pharmaceutical companies worldwide. Titian's Mosaic Sample Management Software encompasses a comprehensive suite of tools for sample tracking, inventory management, and workflow automation. Mosaic empowers laboratories to efficiently manage vast repositories of samples, including compounds, biological materials, and clinical specimens while ensuring data integrity and traceability throughout the sample lifecycle. www.titian.co.uk.
About Battery Ventures
Battery partners with exceptional founders and management teams, developing category-defining businesses in markets including software and services, enterprise infrastructure, online marketplaces, healthcare IT, and industrial technology. Founded in 1983, the firm backs companies at all stages, ranging from seed and early to growth and buyout, and invests globally from six strategic locations: Boston; San Francisco and Menlo Park, Calif.; Tel Aviv; London; and New York. Follow the firm on Twitter @BatteryVentures, visit our website at www.battery.com, and find a complete list of Battery's portfolio companies here.
About Holtzbrinck Digital
Holtzbrinck Digital manages the investments of the Holtzbrinck Publishing Group in digital startups in the science and education sector, as well as other areas of strategic importance. Holtzbrinck Digital supports them in their development with expertise, resources, and a long-term commitment, enabling the companies to achieve the best possible development.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240417562351/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom